Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay
- PMID: 73408
- DOI: 10.1002/1097-0142(197712)40:6<2772::aid-cncr2820400603>3.0.co;2-1
Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay
Abstract
The clinical pharmacology of bleomycin administered by continuous intravenous infusion over a 4 to 5 day period was examined by nine patients. Patients receiving 30 units per day attained an average steady state plasma level of 145.8 (+/- 43.1) ng/ml bleomycin. Elimination of bleomycin was initially described by first order rate kinetics (t 1/2 = 1.32 +/- 0.39 hour). However, at times greater than 12 hours following termination of infusion, a second elimination phase was observed (t 1/2 = 8.9 +/- 2.7 hour). There was also a high correlation between renal bleomycin clearance and creatinine clearance. The importance of renal clearance was indicated in a patient with renal impairment. This patient attained a steady state bleomycin concentration of 1046 ng/ml and exhibited a terminal elimination half-life of 33 hours. Overall plasma clearance of bleomycin (Qbeta) was generally greater than renal clearance, indicating that a nonrenal clearance mechanism was also important in bleomycin elimination. This nonrenal mechanism became especially apparent during renal failure.
Similar articles
-
Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.Cancer Treat Rep. 1977 Dec;61(9):1631-6. Cancer Treat Rep. 1977. PMID: 74282
-
Bleomycin clinical pharmacology by radioimmunoassay.Cancer Chemother Pharmacol. 1982;9(1):22-5. doi: 10.1007/BF00296756. Cancer Chemother Pharmacol. 1982. PMID: 6183016
-
The pharmacokinetics of bleomycin in man.J Clin Pharmacol. 1978 Jul;18(7):346-52. doi: 10.1002/j.1552-4604.1978.tb01604.x. J Clin Pharmacol. 1978. PMID: 78932
-
Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function.Cancer. 1977 Apr;39(4):1430-4. doi: 10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v. Cancer. 1977. PMID: 66973
-
Clevidipine: a review of its use in the management of acute hypertension.Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Am J Cardiovasc Drugs. 2009. PMID: 19331440 Review.
Cited by
-
Combination chemotherapy in malignant non-seminomatous germ-cell tumors: results of a cooperative study of the German Society of Pediatric Oncology (MAKEI 83).Cancer Chemother Pharmacol. 1989;24 Suppl 1:S34-9. doi: 10.1007/BF00253238. Cancer Chemother Pharmacol. 1989. PMID: 2547530 Clinical Trial.
-
A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.Cancer Chemother Pharmacol. 1985;14(3):274-6. doi: 10.1007/BF00258133. Cancer Chemother Pharmacol. 1985. PMID: 2581717
-
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P.J Immunol. 2007 Sep 15;179(6):4035-44. doi: 10.4049/jimmunol.179.6.4035. J Immunol. 2007. PMID: 17785842 Free PMC article.
-
Retrospective Evaluation of a Combination of Carboplatin and Bleomycin for the Treatment of Canine Carcinomas.Animals (Basel). 2022 Sep 8;12(18):2340. doi: 10.3390/ani12182340. Animals (Basel). 2022. PMID: 36139200 Free PMC article.
-
Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002. Clin Pharmacokinet. 1987. PMID: 3555940 Review.